CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.58
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$238.00

14 Apr
2025

4.920

OPEN

$236.22

2.11%

HIGH

$239.60

728,632

LOW

$234.58

TARGET
$327.509 37.6% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 999.0 xxx
DPS (cps) 457.4 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 23.8 xxx
Dividend Yield 1.9% xxx
Div Pay Ratio(%) 45.8% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.58%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.79

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx834.7
DPS All xxxxxxxxxxxxxxx397.4
Sales/Revenue xxxxxxxxxxxxxxx22,417.6 M
Book Value Per Share xxxxxxxxxxxxxxx5,379.9
Net Operating Cash Flow xxxxxxxxxxxxxxx4,218.0 M
Net Profit Margin xxxxxxxxxxxxxxx17.99 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx16.22 %
Return on Invested Capital xxxxxxxxxxxxxxx9.68 %
Return on Assets xxxxxxxxxxxxxxx7.24 %
Return on Equity xxxxxxxxxxxxxxx16.22 %
Return on Total Capital xxxxxxxxxxxxxxx12.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,103.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1,413 M
Long Term Debt xxxxxxxxxxxxxxx16,829 M
Total Debt xxxxxxxxxxxxxxx18,242 M
Goodwill - Gross xxxxxxxxxxxxxxx12,097 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2,481 M
Price To Book Value xxxxxxxxxxxxxxx5.49

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1,919.8 M
Capex % of Sales xxxxxxxxxxxxxxx8.56 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,505 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx5,263 M
Research & Development xxxxxxxxxxxxxxx2,182 M
Investments - Total xxxxxxxxxxxxxxx244 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

12/02/2025

1

Buy

$310.00

30.25%

Ord Minnett notes CSL's 1H25 earnings came below market forecasts, driven by a sharp fall in revenue and earnings from Seqirus while Behring and Vifor turned in solid performances.

Still, the company maintained guidance for full-year net profit growth of 10-13%.

The broker notes the company's confidence was buoyed by strong gross margin performance in Behring which accounts for 67% of group revenue and 63% of earnings.

Following the result, the broker cut its EPS estimates for both FY25 and FY26 by -3% mainly driven by lower expectations from Seqirus.

Target price cut to $310 from $318. Buy rating maintained.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

13/02/2025

2

Overweight

$314.37

32.09%

Jarden highlights CSL's 1H25 result was solid and on balance represented an improvement in the quality of the business.

However, the broker downgraded net profit estimates for FY25 and FY26 by -0.9% and -7.8% on delay in gross margin improvement.

On margins, the broker is disappointed the company retained previous guidance of "100bps plus a bit" improvement in FY25 margins for Behring despite the better-than-expected 170bps rise in 1H. 

Target price cut to $314.37 from $329.62. Jarden maintained its Overweight recommendation, noting the current pricing should offer investors impressive returns with further upside under Horizon 2 initiatives.

FORECAST
Jarden forecasts a full year FY25 dividend of 402.46 cents and EPS of 924.12 cents.
Jarden forecasts a full year FY26 dividend of 437.33 cents and EPS of 990.01 cents.

Wilsons

xx/xx/xxxx

3

xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

CSL STOCK CHART

FNArena News on CSL

1
Rudi’s View: Share Market Scenarios & Dilemmas

Apr 09 2025 - Rudi's View
2
In Brief: US Tariffs & ASX Companies, Plus More

Apr 04 2025 - Weekly Reports
3
Rudi’s View: Coal, Copper, Car Group & More

Mar 27 2025 - Rudi's View
4
Rudi’s View: Captive & Uncomfortable

Mar 26 2025 - Rudi's View
5
Rudi’s View: Best Buys In Copper, Small Caps, Tech, Healthcare, And More

Mar 20 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps